congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
I-DXd
ACCP 2024 | September 8-10, 2024
Concentration-QTc interim analysis of I-DXd in subjects with advanced solid tumors from study IDeate-PanTumor01 (DS7300-A-J101)
Poster
T-DXd
ACCP 2024 | September 8-10, 2024
Exposure-response analyses of efficacy and safety of trastuzumab deruxtecan to inform dosing recommendations in HER2-mutant non–small cell lung cancer
Poster
I-DXd
ACCP 2024 | September 8-10, 2024
Pharmacokinetics and exposure–safety analyses across tumor types for ifinatamab deruxtecan (I-DXd) in the first-in-human IDeate-PanTumor01 study
Poster
HER3-DXd
ACCP 2024 | September 8-10, 2024
Physiologically based pharmacokinetic modeling of a novel HER3-targeted antibody-drug conjugate, patritumab deruxtecan, to assess pharmacokinetic drug-drug interaction
Poster
T-DXd
ACCP 2024 | September 8-10, 2024
Population pharmacokinetics of trastuzumab deruxtecan in subjects with HER2-mutant and HER2-overexpressing non–small cell lung cancer